NEW YORK (GenomeWeb News) – MolecularMD today said it has licensed a genetic marker for the development of diagnostic assays for non-small cell lung cancer.

The Portland, Ore.-based company has licensed the rights to commercialize the intellectual property around the biomarker LKB1 for diagnostic, prognostic, and predictive use, it said. The patent rights for LKB1 are jointly owned by the Dana-Farber Cancer Institute; the Massachusetts General Hospital; the University of North Carolina, Chapel Hill; and the University of Texas Southwestern Medical Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.